RECCE Antibiotic International Media Attention
Released
Released
Announcement PDF
ASX Announcement
RECCE Antibiotic International Media Attention
SYDNEY, Australia, 19 April 2018: Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the
Company), developing a new class of synthetic antibiotics, is pleased to advise that BioWorld, a
recognised biotechnology publication from the United States of America, has recently published a
significant and unpaid article on the Company.
The article highlights the unique ability of RECCE® 327 to potentially overcome the world’s superbug
health crisis, whilst further elaborating on recent regulatory and operational advances, which the
Company wishes to provide to its shareholders and encourages shareholders to read. Some
important topics expanded upon within the article include:
•
RECCE® 327 as a new class of synthetic antibiotic and its universal ‘master key’ approach to
overcoming the growing threat of antibiotic resistance (superbugs).
•
Disrupting the antibiotic industry business models through its unique ability to never succumb
to antibiotic resistance – restricted usage could become a thing of past.
•
The FDA awarded Qualified Infectious Disease Product (QIDP) designation for RECCE® 327
as a broad-spectrum antibiotic provides for expedited review and 10 years of market
exclusivity.
•
The Company’s up-coming meeting with the FDA in May to discuss a regulatory pathway for
RECCE® 327.
A copy of the article is available below and will soon be published on the Company’s website at
www.recce.com.au, under the section ‘Investors & Media’.
BioWorld
The news source of record covering the development of innovative human therapies
Actionable Intelligence • Incisive Analysis
April 11, 2018
Volume 29, No. 70
Special Reprint
Recce nears clinic with ‘master key’ antibiotic to take on superbugs
By Tamra Sami, Staff Writer
PERTH, Australia – A new class of synthetic antibiotics with
broad-spectrum activity is being developed by Sydney-based
Recce Pharmaceuticals Ltd. that could solve the problem of
antibiotic resistance.
“We have a completely new class of antibiotics, and there has
not been a new class of antibiotics worldwide for around 30
years,” Recce Executive Director Michele Dilizia told BioWorld.
“Typically antibiotics are either derived from natural sources
such as penicillin or they’ve been modified to give them
additional spectrum of activity. Our antibiotic is completely
different because it is entirely synthetic,” said Dilizia, who is
also a co-inventor of the technology.
“Not only is it a new class that will tackle all bacteria, including
superbugs, but it will keep on killing and not be vulnerable
to any attempt by bacteria to mutate and overcome our
mechanism of action.”
She explained that traditional antibiotics operate on a lockand-key mechanism such that the antibiotic will look for
a specific part of the bacterial membrane, lock into it, and
destroy the bacteria. But as soon as the bacteria mutate, the
antibiotic stops working.
Comparatively, Recce’s mechanism of action is “universal,”
akin to a “master key” to the bacterial membrane so that the
antibiotic adheres to the outside membrane of the bacteria,
reacts with the protein, and destroys the bacteria.
“It will not only kill the bacteria, but because it is a universal
means of killing, any mutation is rendered of no consequence,”
Dilizia said.
Executive Director James Graham said that traditional
antibiotics have one, two or three active sites, but as a polymer,
Recce’s compound has millions of active sites.
“We have an extremely powerful antibiotic that has been
able to kill every bacteria it has tested against,” Graham said.
“We are breaking the paradigm of antibiotic use through a
completely different mechanism of action.”
Lead candidate Recce 327 was developed for treating blood
infections and sepsis derived from Escherichia coli and
Staphylococcus aureus bacteria, including their superbug
forms.
Sepsis affects around 30 million people worldwide, and onethird of them die within the first 24 hours, according to Recce.
Founder and inventor Graham Melrose, who now serves as
the company’s executive chairman, has a strong background
in polymer chemistry and was formerly head of research
with Johnson & Johnson. He wanted to continue the work
he was doing at J&J and set up his own lab in Perth where he
developed Recce 327. Dilizia joined him and helped set up a
more intensive microbiology lab, growing bacteria, developing
tests and confirming the activity of the compound.
The compound was tested against a wide range of bacteria,
including a deadly strain of E. coli that was resistant to all
antibiotics. Dilizia said the agar plates were spotless, and there
was no organism they tested that could not be killed.
Preclinical results in mice for methicillin-resistant
Staphylococcus aureus (MRSA) were also positive.
FDA QIDP status granted
The FDA awarded Recce 327 qualified infectious disease
product (QIDP) designation as a broad-spectrum antibiotic,
used intravenously against E. coli and Staphylococcus aureus
bacteria in the blood, including their superbug forms. The QIDP
designation provides for an expedited review and 10 years of
market exclusivity.
QIDP designation is part of the U.S. Generating Antibiotic
Incentives Now (GAIN) Act and was formed to encourage drug
companies to develop new treatments for antibiotic-resistant
organisms known to cause serious or life-threatening infections.
“The fact that Recce 327 meets the FDA’s criteria for qualified
infectious disease product designation is a tremendous
validation of our strategy to invest in synthetic polymers as
potentially a whole new-class of antibiotics, said Melrose.
In February, Recce submitted additional data to the FDA that
included expanded preclinical data and a proposed phase I trial
program.
The company has a meeting scheduled with the FDA in May
to discuss the regulatory pathway for Recce 327. Graham said
U.S. phase I trials could begin later this year. Recce plans on
targeting the American market first since roughly 47 percent of
the antibiotic market is in the U.S.
As a broad-spectrum antibiotic, the technology is applicable
to a range of infections and formulations, and Recce plans on
creating a portfolio of products, including an oral formulation
for Helicobacter pylori and other applications. For now, it is
focusing on the I.V. formulation first to treat the most urgent
health needs.
©2018. Reprinted with permission from Clarivate Analytics.
For Sales Inquiries: http://clarivate.com/life-sciences/news/bioworld/#. NORTH AMERICA, Tel: +1-855-260-5607. Outside of the U.S. and Canada, Tel. +44-203684-1797. For Customer Service Inquiries, NORTH AMERICA, Tel: +1-800-336-4474. Outside of the U.S. and Canada, Tel. +44-203-684-1796.
Wednesday, April 11, 2018
BioWorld
“We are looking to break the antibiotic business model,”
Graham said. “Physicians are trying not to prescribe antibiotics
for fear of them becoming resistant, but less prescriptions
means less sales, and less sales means less return on
investment, so less motivation to develop new antibiotics.
“If you have a drug that does not become resistant, no matter
how many exposures, you break the current block on the
industry, because the physician can prescribe the antibiotic
without fear of it becoming resistant.
“This could be the biggest thing since penicillin,” Graham said,
noting that penicillin was discovered in Australia, but it couldn’t
find funding here; it finally found support in the U.S.
Meanwhile, governments around the world are taking both
a carrot and stick approach to entice pharma companies
to develop new antibiotics by trying to fine them for not
developing new antibiotics and at the same time offering huge
rewards.
Recce has its eyes on the Combating Antibiotic-Resistant
Bacteria Biopharmaceutical Accelerator (CARB-X) global
initiative, which is offering a $1 billion reward for each new
© 2018 Clarivate Analytics
Page 2 of 2
antibiotic approved, as well as increased R&D funding.
The QIDP designation is making big waves among Australian
investors, Graham said.
The Australian government awarded its R&D tax credit
for Recce’s clinical trials in the U.S., which is an unusual
move, because it means that Australian taxpayers will pay
43.5 percent of the company’s R&D expenses to support its
international development. The tax credit is normally awarded
for companies developing drugs in Australia and is intended to
support clinical trials in Australia.
Manufacturing capability in Australia will allow Recce to control
the process while also keeping the knowledge in Australia,
Dilizia added.
With a market cap of A$21 million (US$16 million), Recce
listed on the Australian Securities Exchange (ASX:RCE) in
January 2016. It raised A$5 million in its IPO, and the funds
raised helped the complete preclinical trials and establish a
manufacturing facility to prepare for phase I trials. Graham said
the company has completed those goals and will raise money
to conduct phase I trials. s
Share your feedback
Discover